Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.46 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31179229 | 1.00 | CYP3A4 (0.54) | CYP3A4ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL4088198 | 0.83 | ALDH1A1 (0.54) | CYP3A4ALDH1A1TSHRHPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL31178856 | 0.81 | ALDH1A1 (0.52) | CYP3A4ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL29498391 | 0.77 | PLAU (0.63) | CYP3A4ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL731002 | 0.77 | PLAU (0.63) | CYP3A4ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL29404930 | 0.77 | PLAU (0.63) | CYP3A4ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL30366437 | 0.77 | CYP1A2 (0.58) | CYP3A4ALDH1A1TSHRCYP2A6NR4A2 | |
| SCHEMBL30366566 | 0.77 | CYP1A2 (0.58) | CYP3A4ALDH1A1TSHRCYP2A6NR4A2 | |
| SCHEMBL1780245 | 0.77 | CYP1A2 (0.58) | CYP3A4ALDH1A1TSHRCYP2A6NR4A2 | |
| SCHEMBL29351158 | 0.76 | ALDH1A1 (0.62) | CYP3A4ALDH1A1TSHRHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORP (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4558479-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-4548918-A2 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024017858-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| EP-4087843-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2022-11-16 | — | — | EP | disclosed |
| US-10793584-B2 | Naphthobischalcogenadiazole derivative and production method therefor | OSAKA UNIVERSITY (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190337966-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | OSAKA UNIVERSITY (JP) | 2019-11-07 | — | — | US | disclosed |
| US-10398679-B2 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors | ITEOS THERAPEUTICS (BE) | 2019-09-03 | — | — | US | disclosed |
| US-10398679-B2 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors | ITEOS THERAPEUTICS (BE) | 2019-09-03 | — | — | US | disclosed |
| CN-106536480-B | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | 艾特奥斯治疗公司 | 2019-09-03 | — | — | CN | disclosed |
| US-20170035731-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2017-02-09 | — | — | US | disclosed |
| US-20170035731-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2017-02-09 | — | — | US | disclosed |
| US-20150329525-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | US | disclosed |
| WO-2015173764-A1 | PYRROLIDINE-2,5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | ITEOS THERAPEUTICS (BE) | 2015-11-19 | — | — | WO | disclosed |
| CN-1863784-B | 2-naphthylimino-1,3-thiazine derivative | SHIONOGI & CO | 2010-11-17 | — | — | CN | disclosed |
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| CN-1863784-A | 2-naphthylimino-1,3-thiazine derivative | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005123089-A2 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793584-B2 | Naphthobischalcogenadiazole derivative and production method therefor | CYP24A1, CYP26B1, CYP21A2 | CYP3A4 389/4885ALDH1A1 600/4885TSHR 1397/4885 |
| US-20190337966-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | CYP24A1, CYP26B1, CYP21A2 | CYP3A4 389/4885ALDH1A1 600/4885TSHR 1397/4885 |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | CYP3A4 95/4885ALDH1A1 1571/4885TSHR 440/4885 |
| US-20250188073-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | KRAS, NRAS, HRAS | CYP3A4 3923/4885ALDH1A1 2204/4885TSHR 4621/4885 |
| US-20170035731-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | IDO1, IDO2, ARG1 | CYP3A4 905/4885ALDH1A1 357/4885TSHR 4401/4885 |
| US-20150329525-A1 | PYRROLIDINE-2, 5-DIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE AS IDO1 INHIBITORS | IDO1, IDO2, ARG1 | CYP3A4 437/4885ALDH1A1 212/4885TSHR 4368/4885 |
| US-10398679-B2 | Treatment method utilizing pyrrolidine-2, 5-dione derivatives as IDO1 inhibitors | IDO1, IDO2, NAT1 | CYP3A4 910/4885ALDH1A1 241/4885TSHR 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.